Comparing tailored therapy to standard treatment for Helicobacter pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of susceptibility-guided tailored therapy (SG-TT) versus guidelines-recommended empiric therapy (GR-ET) for patients with Helicobacter pylori infection who have previously failed treatment. It will involve a multicenter, randomized approach where patients will be assigned to one of the two treatment groups based on a randomization process. The study will also assess patient adherence, adverse effects, and factors influencing treatment success. Participants will be monitored throughout the treatment period to gather data on symptoms and medication use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients, aged \>= 20, having H. pylori-positive chronic gastritis with/without peptic ulcers (duodenal or gastric ulcers) will be recruited. If the patients failed anti-H. pylori therapy previously, they will be invited to enter this study for evaluating the efficacy of these rescue regimens.

Exclusion Criteria:

1. pregnant or nursing woman;
2. serious concomitant illness and malignant tumor of any kind;
3. history of hypersensitivity to test drugs；
4. serious bleeding during the course of this ulcer;
5. previous gastric surgery;
6. receiving bismuth salts, PPIs, or antibiotics in the previous month.

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Jyh-Chin Yang, M.D.Ph.D. — National Taiwan University Hospital
• Study coordinator: Jyh-Chin Yang, M.D.Ph.D.
• Email: jcyang47@ntu.edu.tw
• Phone: 02-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

• P-CABs plus bismuth quadruple treatment for Helicobacter pylori infection

  This study tests whether using potassium-competitive acid blockers (P-CABs) in bismuth-containing quadruple therapy works better and is safe for adults with H. pylori infection.

  Recruiting Qilu Hospital of Shandong University · Jinan · NCT07285096

• Bismuth versus no bismuth for treating H. pylori-related stomach and duodenal ulcers in children

  This project will try adding bismuth to standard antibiotic and PPI treatment to see if it helps clear H. pylori and heal ulcers in children.

  Recruiting Can Tho University of Medicine and Pharmacy · Can Tho · NCT07260006

• Tegoprazan 50 mg twice daily plus amoxicillin versus vonoprazan 20 mg twice daily plus amoxicillin for H. pylori eradication

  This trial tests whether a 14-day tegoprazan plus amoxicillin regimen works as well as a vonoprazan plus amoxicillin regimen to cure Helicobacter pylori infection in adults.

  Recruiting Phase 2/3 First People's Hospital of Hangzhou · Hangzhou, Zhejiang · NCT07242456

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.